Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Reduced Intensity HSCT for Sickle Cell and Thalassemia
NCT02435901Phase 2Completed
- Sponsor
- Northwell Health
- Start
- Dec 2008
- Primary completion
- Mar 2019
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of allogeneic hematopoietic stem cells in sickle cell disease (SCD), beta thalassemia, sponsored by Northwell Health. Started Dec 2008; status: completed.
02
Drugs
allogeneic hematopoietic stem cells
03
Conditions
sickle cell disease (SCD)beta thalassemia
Beyond the preview
Go deeper on NCT02435901.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02435901.